A Texas-based company founded as Lung Therapeutics in 2013 and acquired by Aileron Therapeutics in 2023 announced that it has now changed its name to Rein Therapeutics. Lung Therapeutics spun off TFF Pharmaceuticals in 2018 to develop dry powders based on thin film freezing technology licensed from the University of Texas.
Rein Therapeutics President and CEO Brian Windsor was President of particle engineering company Enavail prior to becoming President and CEO of Lung Therapeutics and then founder and Chief Science Officer of TFF Pharmaceuticals. In September 2024, TFF Pharmaceuticals announced that it would perform a feasibility study of an Emory University mRNA-based antiviral; however, the company announced in November 2024 that it would cease operations.
Rein’s lead candidate is LTI-03, an inhaled dry powder caveolin-1 scaffolding domain peptide for the treatment of idiopathic pulmonary fibrosis. Aileron announced results from a Phase 1b trial of LTI-03 in November 2024, and Rein says that it expects to initiate a Phase 2 trial by mid-2025.
Windsor commented, “Our rebrand to Rein Therapeutics reflects our unwavering commitment to address the critical needs of underserved patients with fibrotic diseases. This new chapter for the company underscores our focus on reining in fibrosis and advancing our pipeline of novel candidates. We look forward to the initiation of a Phase 2 clinical trial for our lead candidate, LTI-03, in the first half of this year, aiming to bring hope to those affected by idiopathic pulmonary fibrosis.”
Read the Rein Therapeutics press release
